Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tacrolimus has immunosuppressive effects on heavy/light chain pairs and free light chains in patients after heart transplantation: A relationship with infection

P. Lavríková, P. Sečník, Z. Kubíček, A. Jabor, L. Hošková, J. Franeková,

. 2018 ; 50 (-) : 43-47. [pub] 20180615

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19012610

Grant support
NV15-27579A MZ0 CEP Register

The aim of the study was to investigate the relationship between tacrolimus (TAC) immunosuppressive treatment and serum concentrations of immunoglobulin heavy/light chain pairs (sHLC) and free light chains (sFLC) in patients after heart transplantation (HTX) and to use these biomarkers to predict the risk of infection in these patients. A total of 88 patients with an immunosuppressive regimen involving tacrolimus who underwent HTX were analyzed over 24 months of follow-up. sFLC and sHLC levels were determined before and at three time points after HTX. TAC concentrations were determined at several time points after HTX, and mean TAC concentrations and areas under the curve (AUCs) of TAC concentration were calculated. Relevant clinical data were obtained from patients' medical records. A larger AUC of TAC was associated with decreases in the concentrations of IgG total (p < 0.05); similarly, cumulative AUC of TAC during 18 post-transplant months correlated inversely with sHLC IgG kappa (r = -0.228, p < 0.05) and IgG total (r = -0.352, p < 0.05). Concentrations of sFLC kappa, sFLC lambda, sHLC IgG kappa, and sHLC IgG total were significantly lower in infected patients (in the 9th month after HTX, all p < 0.05). Combined criteria for increased AUC (greater than the median of 12.9 mg·d/l) and decreased sFLC kappa (less than the median of 12.5 mg/l) correlated with the presence of infection (p < 0.03) in the 9th month after HTX. Ratio of concentration of TAC to sFLC kappa or lambda was significantly higher in infected patients (both p < 0.05). Intensive treatment with tacrolimus after HTX is possibly reflected by decreases in sFLC and sHLC (mainly sHLC IgG). Patients with decreased concentrations of these biomarkers are at increased risk for infection, primarily in the 9th month after HTX, when the concentrations of tacrolimus were the highest.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012610
003      
CZ-PrNML
005      
20210720101502.0
007      
ta
008      
190405s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.trim.2018.06.005 $2 doi
035    __
$a (PubMed)29913223
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Lavríková, Petra $u Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, CZ-14021 Prague, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Praha 10, Czech Republic. Electronic address: petra.lavrikova@ikem.cz.
245    10
$a Tacrolimus has immunosuppressive effects on heavy/light chain pairs and free light chains in patients after heart transplantation: A relationship with infection / $c P. Lavríková, P. Sečník, Z. Kubíček, A. Jabor, L. Hošková, J. Franeková,
520    9_
$a The aim of the study was to investigate the relationship between tacrolimus (TAC) immunosuppressive treatment and serum concentrations of immunoglobulin heavy/light chain pairs (sHLC) and free light chains (sFLC) in patients after heart transplantation (HTX) and to use these biomarkers to predict the risk of infection in these patients. A total of 88 patients with an immunosuppressive regimen involving tacrolimus who underwent HTX were analyzed over 24 months of follow-up. sFLC and sHLC levels were determined before and at three time points after HTX. TAC concentrations were determined at several time points after HTX, and mean TAC concentrations and areas under the curve (AUCs) of TAC concentration were calculated. Relevant clinical data were obtained from patients' medical records. A larger AUC of TAC was associated with decreases in the concentrations of IgG total (p < 0.05); similarly, cumulative AUC of TAC during 18 post-transplant months correlated inversely with sHLC IgG kappa (r = -0.228, p < 0.05) and IgG total (r = -0.352, p < 0.05). Concentrations of sFLC kappa, sFLC lambda, sHLC IgG kappa, and sHLC IgG total were significantly lower in infected patients (in the 9th month after HTX, all p < 0.05). Combined criteria for increased AUC (greater than the median of 12.9 mg·d/l) and decreased sFLC kappa (less than the median of 12.5 mg/l) correlated with the presence of infection (p < 0.03) in the 9th month after HTX. Ratio of concentration of TAC to sFLC kappa or lambda was significantly higher in infected patients (both p < 0.05). Intensive treatment with tacrolimus after HTX is possibly reflected by decreases in sFLC and sHLC (mainly sHLC IgG). Patients with decreased concentrations of these biomarkers are at increased risk for infection, primarily in the 9th month after HTX, when the concentrations of tacrolimus were the highest.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a nežádoucí účinky léčiv $x epidemiologie $7 D064420
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a rejekce štěpu $x etiologie $x prevence a kontrola $7 D006084
650    12
$a transplantace srdce $7 D016027
650    _2
$a lidé $7 D006801
650    _2
$a těžké řetězce imunoglobulinů $x krev $7 D007143
650    _2
$a lehké řetězce imunoglobulinů $x krev $7 D007147
650    _2
$a imunosupresiva $x škodlivé účinky $x terapeutické užití $7 D007166
650    _2
$a infekce $x epidemiologie $x etiologie $7 D007239
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a riziko $7 D012306
650    _2
$a takrolimus $x škodlivé účinky $x terapeutické užití $7 D016559
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sečník, Peter $u Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, CZ-14021 Prague, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Praha 10, Czech Republic. Electronic address: peter.secnik@ikem.cz.
700    1_
$a Kubíček, Zdenek, $u Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, CZ-14021 Prague, Czech Republic. $d 1946- $7 jo2015865150
700    1_
$a Jabor, Antonín $u Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, CZ-14021 Prague, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Praha 10, Czech Republic. Electronic address: anja@medicon.cz.
700    1_
$a Hošková, Lenka $u Cardiology Clinic, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, CZ-14021 Prague, Czech Republic. Electronic address: lenka.hoskova@ikem.cz.
700    1_
$a Franeková, Janka $u Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, CZ-14021 Prague, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Praha 10, Czech Republic. Electronic address: jafa@ikem.cz.
773    0_
$w MED00006022 $t Transplant immunology $x 1878-5492 $g Roč. 50, č. - (2018), s. 43-47
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29913223 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20210720101459 $b ABA008
999    __
$a ok $b bmc $g 1391920 $s 1050915
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 50 $c - $d 43-47 $e 20180615 $i 1878-5492 $m Transplant immunology $n Transpl Immunol $x MED00006022
GRA    __
$a NV15-27579A $p MZ0
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options